Spring Bank Pharmaceuticals’ (NASDAQ:SBPH) Buy Rating Reiterated at Chardan Capital

Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH)‘s stock had its “buy” rating restated by analysts at Chardan Capital in a research report issued on Monday, November 6th.

A number of other research analysts also recently issued reports on SBPH. Cantor Fitzgerald started coverage on Spring Bank Pharmaceuticals in a research note on Wednesday, July 19th. They set an “overweight” rating and a $29.00 target price for the company. ValuEngine downgraded Spring Bank Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Dawson James reiterated a “buy” rating on shares of Spring Bank Pharmaceuticals in a research note on Monday, August 7th. Finally, B. Riley started coverage on Spring Bank Pharmaceuticals in a report on Monday, November 6th. They set a “buy” rating and a $30.00 price target for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $27.25.

Spring Bank Pharmaceuticals (SBPH) traded up $0.11 during midday trading on Monday, hitting $15.29. The stock had a trading volume of 18,296 shares, compared to its average volume of 45,119. Spring Bank Pharmaceuticals has a 52 week low of $6.31 and a 52 week high of $18.93.

A number of hedge funds and other institutional investors have recently made changes to their positions in SBPH. Sphera Funds Management LTD. bought a new position in shares of Spring Bank Pharmaceuticals in the 2nd quarter valued at $2,370,000. Morse Asset Management Inc grew its position in Spring Bank Pharmaceuticals by 94.7% during the 3rd quarter. Morse Asset Management Inc now owns 124,000 shares of the company’s stock worth $2,004,000 after acquiring an additional 60,300 shares during the last quarter. AXA bought a new stake in Spring Bank Pharmaceuticals during the 2nd quarter worth $2,894,000. C WorldWide Group Holding A S grew its position in Spring Bank Pharmaceuticals by 342.6% during the 3rd quarter. C WorldWide Group Holding A S now owns 111,200 shares of the company’s stock worth $1,873,000 after acquiring an additional 86,077 shares during the last quarter. Finally, Private Capital Advisors Inc. grew its position in Spring Bank Pharmaceuticals by 50.0% during the 2nd quarter. Private Capital Advisors Inc. now owns 56,250 shares of the company’s stock worth $762,000 after acquiring an additional 18,750 shares during the last quarter. 29.24% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Spring Bank Pharmaceuticals’ (NASDAQ:SBPH) Buy Rating Reiterated at Chardan Capital” was first posted by BBNS and is owned by of BBNS. If you are reading this piece on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece can be read at https://baseballnewssource.com/markets/spring-bank-pharmaceuticals-inc-sbph-given-buy-rating-at-chardan-capital/1762251.html.

Spring Bank Pharmaceuticals Company Profile

Spring Bank Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases.

Analyst Recommendations for Spring Bank Pharmaceuticals (NASDAQ:SBPH)

Receive News & Ratings for Spring Bank Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Phillies Sign Free Agent Carlos Santana
Phillies Sign Free Agent Carlos Santana
Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Manny Machado Could Change Positions or Uniforms
Manny Machado Could Change Positions or Uniforms
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle


Leave a Reply

 
© 2006-2017 BBNS.